Rapid, Accurate Test Results in ~30-minutes

Test, diagnose and treat in a single visit with the first and only FDA-cleared, CLIA-waived, point-of-care platform for CT/NG testing for males and females.

Together, we can help stop the spread

STIs are on the rise and testing pathways are struggling to keep up.

Traditional pathway

Sample sent to central reference laboratory

Test results available

1-10 days

Treatment may be potentially inappropriate, before leaving the clinic

binx io pathway

Sample ran on binx io point-of-care test

Test results available

~30 mins

Increases treatment compliance with same visit test and treatment

--The power of a central lab at the touch of a button--

The FDA-cleared, CLIA-waived, binx io platform uses ultra-rapid polymerase chain reaction (PCR) amplification in conjunction with binx health’s proprietary electrochemical detection to achieve sensitivity and specificity equivalent to central lab performance.

CLIA-Waived & FDA-Cleared
Lab-quality results at the point-of-care
Single-visit results and treatment
Asymptomatic and symptomatic testing
Established reimbursement

Clinically-Proven, FDA-Cleared

Clinical performance measured against three FDA-cleared standard-of-care molecular platforms


2,445 person (1,523 females; 992 males) multi-center clinical study As published in JAMA Network Open
Van Der Pol, B. et al. Evaluation of the Performance of a Point-of-Care Test for Chlamydia and Gonorrhoea. JAMA Network Open 3(5) (2020): e204819


Featured in Published Literature

The binx io is recognized in the industry for revolutionizing STI diagnostic testing at the point-of-care. We’re featured in published medical journals and have received industry awards for our technological advances.

How it works

Learn how the binx io is transforming diagnostics with rapid results at the point-of-care

Ready to Bring STI Testing to Your Community?

Learn how the binx io can improve your community health outcomes and drive revenue for your clinic today.